alvircept sudotox
Recombinant proteinexperimental
Alvircept sudotox is a form of recombinant CD4 derived from Pneumonas aeruginosa exotoxin A, or 'PE40, which has a size of 59,187 daltons and is an anti-viral agent. — Wikipedia
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002087)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T-cell surface antigen CD4INHIBITOR
CD4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAlvircept sudotox ↗
- ChEMBLCHEMBL2108842 ↗
Also known as
- alvircept sudotox
- alvircept sudotox
- alvircept sudotox
- scd4-pe40
- u-85855
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000743 | Phase 1 | Nov 2, 1999 | Glaxo Wellcome, National Institute of Allergy and Infectious Diseases (NIAID), Upjohn |
| NCT00002087 | Phase 1 | Nov 2, 1999 | Pharmacia & Upjohn |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Glaxo Wellcome | For profit | 1 | 0 | 1 | 1999 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 1999 |
| Pharmacia & Upjohn | For profit | 1 | 1 | 1 | 1999 |
| Upjohn | For profit | 1 | 0 | 1 | 1999 |
4 organizations
Page 1 / 1